TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01649297
Drug: empagliflozin (low dose bid)
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients receive Empagliflozin low dose split twice daily
Study: NCT02648711
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: infusion weekly CRLX101 + bevacizumab biweekly
Study: NCT00358436
Drug: Aclidinium bromide
Normalized name: Aclidinium Bromide
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aclidinium bromide 200 μg once-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
Study: NCT00765063
Drug: Fragmin
Normalized name: Fragmin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium
Study: NCT02815592
Drug: BMS-986012
Normalized name: BMS-986012
DrugBank: BMS-986012 (DB14831)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02815592
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02815592
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02815592
Drug: Platinum
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02815592
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04435028
Drug: Ketotifen 1 MG
Normalized name: ketotifen 1 MG
DrugBank: Ketotifen (DB00920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketotifen is added to patients on anthracycline-containing chemotherapy for 6 months
Study: NCT00951964
Drug: Polyphenon E before Placebo
Normalized name: Polyphenon E
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receive polyphenon E during 4 months, then 2 months of wash-out and finally 4 months of placebo
Study: NCT01061853
Drug: TOPICAL SIROLIMUS (RAPAMUNE*)
Normalized name: sirolimus Topical Product
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: APPLICATION ON THE LESIONS OF TOPICAL SIROLIMUS (RAPAMUNE\*)1mg/ml bid during 3 months
Study: NCT01061853
Drug: TOPICAL BETAMETHASONE 0.05%
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: APPLICATION ON THE LESIONS OF TOPICAL BETAMETHASONE (DIPROLENE\*)0.05% bid during 3 months
Study: NCT00003597
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003597
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04510610
Drug: Camrelizumab and Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function. Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
Study: NCT00397020
Drug: divalproex ER
Normalized name: divalproex sodium Extended Release Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: 30mg per kg, rounded to nearest 500mg, dosed PO QHS. Adjustments made through trial to obtain serum valproic acid levels of 85-125 mcg/ml
Study: NCT00397020
Drug: quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: 200mg PO QHS, titrated up to therapeutic dose of 600-800mg.
Study: NCT00822666
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: comparison of two loading strategies of clopidogrel (300mg vs 900mg) in the two genetic profiles
Study: NCT01327027
Drug: Vasopressin, Arginine, ADH
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin will be dissolved in sterile saline and intranasally delivered in one of 2 doses to each subject (20IU, 40IU)
Study: NCT00305539
Drug: adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 40 mg sc / for 3 months
Study: NCT01438450
Drug: Oral
Normalized name: Doral
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capecitabine : 500 mg OD x 1 week 500 mg BD x 1 week 500 mg (2 morning, 1 evening) x 1 week After attaining the max dose of 1500 mg, a cycle of Capecitabine 1500mg every day for 2 weeks and 1 week off to be maintained.~Thalidomide: 50 mg OD x 1 week 100 mg OD x 1 week 200 mg OD x 1 week, 300 mg OD x 1 week
Study: NCT00610311
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m\^2 day intravenous piggy back over 30 minutes for 5 days
Study: NCT03558971
Drug: Cortisol
Normalized name: Cortisol
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants determine when to administer 5-day regimens of cortisol
Study: NCT01559701
Drug: PF-00345439
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-80 mg twice-a-day for 12 months
Study: NCT02735356
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied topically
Study: NCT00108498
Drug: mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01874665
Drug: Ponatinib
Normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ponatinib 45 mg, tablets, orally, once-daily.
Study: NCT01504841
Drug: Etravirine (ETR)
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ETR was administered as 25-mg scored tablets and/or 100-mg tablets swallowed whole or dispersed in an appropriate liquid vehicle following a meal. Children took the specified dose orally twice daily within 30 minutes following a meal. Dose was decided according to dosing tables in protocol.
Study: NCT00257361
Drug: D-Cycloserine
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04218773
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive intravenous phenylephrine at a rate of 60 µg/min. The infusion rate will be adjusted at 30 µg/min increments (maximum 180 µg/min) at 3-minute intervals to maintain an increase in SBP to the target SBP of 160 - 220 mmHg or a 20% increase above baseline SBP values.
Study: NCT02708433
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine
Study: NCT01860807
Drug: Ibudilast
Normalized name: ibudilast
DrugBank: Ibudilast (DB05266)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT00572208
Drug: Gabapentin group
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin group:~Preoperative (2 h before surgery): Tablet Gabapentin 1200 mg (blinded)~1. st Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~2. nd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~3. rd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~4. th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~5. th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)
Study: NCT00746434
Drug: Roflumilast cream
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast cream 0.5%
Study: NCT02726035
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral naltrexone 50 mg daily
Study: NCT02874573
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Investigational agent
Study: NCT00677092
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 400 mg p.o. daily for 4 months. Dosage was reduced to 200 mg if participants develop gastrointestinal intolerance or alopecia.
Study: NCT01274559
Drug: Extended-release niacin/laropiprant (ERN/LRPT)
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 oral 1 g tablet of ERN/LRPT to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of ERN/LRPT to be taken together in the evening or at bedtime with food for the next 8 weeks. Each 1g tablet contains 1g ERN and 20 mg LRPT
Study: NCT01340300
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral metformin QD for two weeks, then BID
Study: NCT03883698
Drug: Sofosbuvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir is the backbone of the most of the currently used anti-HCV treatment regimens
Study: NCT03883698
Drug: Daclatasvir 60 mg
Normalized name: daclatasvir 60 MG
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclatasvir, in combination with sofosbuvir, is approved for the treatment of hepatitis C virus infection in absence of liver cirrhosis
Study: NCT01435629
Drug: somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage and administration to be prescribed by the physician as a result of a normal clinical practice.
Study: NCT02575170
Drug: Amino acid solution
Normalized name: NephrAmine 5.4% Essential Amino Acid Solution for Injection
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a balanced mixture of 18 pure crystalline amino acids, eight of which are essential amino acids
Study: NCT01225172
Drug: BMS-754807
Normalized name: BMS-754807
DrugBank: BMS-754807 (DB15399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity
Study: NCT03437577
Drug: immediate-release tacrolimus
Normalized name: tacrolimus Extended Release Oral Tablet
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care for transplant patients
Study: NCT01225172
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 2.5 mg, Daily, Until disease progression or unacceptable toxicity
Study: NCT03437577
Drug: extended release tacrolimus
Normalized name: tacrolimus Extended Release Oral Tablet
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental care
Study: NCT00550381
Drug: HKI-357
Normalized name: HKI-357
DrugBank: HKI-357 (DB13002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose capsule
Study: NCT02870634
Drug: Cu(II)ATSM
Normalized name: Cu(ii)atsm
DrugBank: Copper(II) dithiosemicarbazone (DB16963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: copper-containing synthetic small molecule
Study: NCT00625781
Drug: Insulin aspart and Insulin human (isophane)
Normalized name: insulin aspart, human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment if fasting p-glucose \>5.0 mmol/l or post meal value \>6.5 mmol/l according to study protocol.
Study: NCT02493049
Drug: Domperidone
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of Domperidone to current Disease Modifying Therapy.
Study: NCT00023712
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00742846
Drug: Lidocaine + Kenalog
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5ml 1% Lidocaine + 1ml 40mg Kenalog®-10 into the shoulder joint~Intra-articular injection with local anesthetic and steroid
Study: NCT00742846
Drug: Lidocaine + Kenalog
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5ml 1% Lidocaine + 1ml 40mg Kenalog-10 into the subacromial space~Local anesthetic and steroid in to the subacromial space
Study: NCT02215330
Drug: Maltodextrin
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01858480
Drug: D-ribose
Normalized name: D-Ribose
DrugBank: Ribose (DB15073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-ribose powder for oral solution and D-ribose for injection.
Study: NCT00853229
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pregabalin 150mg twice daily for 4 weeks
Study: NCT03694262
Drug: Rucaparib
Normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rucaparib 600mg orally twice daily by continuous dosing
Study: NCT03694262
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15mg/kg IV on day 1 of every cycle
Study: NCT03694262
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1,200mg IV on day 1 of every cycle
Study: NCT03600649
Drug: Seclidemstat
Normalized name: Seclidemstat
DrugBank: Seclidemstat (DB17117)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily administration of seclidemstat
Study: NCT03600649
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.75 mg/m2/day on Days 1 thru 5 of a 21-day cycle
Study: NCT02429687
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT02429687
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT02106494
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02106494
Drug: Ondansetron placebo
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02106494
Drug: Fosaprepitant
Normalized name: Fosaprepitant
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02106494
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02997059
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg/ day
Study: NCT02429687
Drug: Bleomycin
Normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
Study: NCT02429687
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.
Study: NCT03361098
Drug: Dapagliflozin 10mg
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10mg oral tablet once daily
Study: NCT03361098
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide 5 microgram b.i.d. week 1-4 Exenatide 10 microgram b.i.d. week 5-16
Study: NCT00742846
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5ml 1% Lidocaine alone into the shoulder joint.~intra-articular local anesthetic injection
Study: NCT02429687
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
Study: NCT01006499
Drug: Pentoxifylline, pentaglobin
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentaglobin 250mg/kg/d over 4 hour for three days Pentoxyfilline 6mg/kg/h over 4 hour for three days Pentaglobin 250mg/kg/d over 4 hour for three days+Pentoxyfilline 6mg/kg/h over 4 hour for three days Placebo (normal saline 5ml/kg over 4 hour for three days
Study: NCT02261090
Drug: Formulation B: Pramipexole Slow release (SR) tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02261090
Drug: Formulation C: Pramipexole Slow release tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02261090
Drug: Formulation D: Pramipexole Slow release tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02261090
Drug: Formulation E: Pramipexole Slow release tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02261090
Drug: Formulation F: Pramipexole Slow release tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02261090
Drug: Formulation G: Pramipexole Slow release tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02261090
Drug: Formulation H: Pramipexole Slow release tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02261090
Drug: Pramipexole immediate release (IR) tablets
Normalized name: pramipexole Extended Release Oral Tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00753883
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe 10 mg/QD for 8 weeks.
Study: NCT00742846
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5ml 1% Lidocaine alone into the subacromial space.~subacromial local anesthetic injection
Study: NCT01948063
Drug: Ubiquinol
Normalized name: Ubiquinol
DrugBank: Ubiquinol (DB11340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.
Study: NCT02005068
Drug: Ceftaroline
Normalized name: Ceftaroline
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The duration of treatment will vary based on type of infection (acute osteomyelitis or joint infection) and if MRSA positive or negative.
Study: NCT02650986
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00171418
Drug: Tegaserod
Normalized name: Tegaserod
DrugBank: Tegaserod (DB01079)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02208037
Drug: Tacrolimus (ARM with Methotrexate)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels. The dose should be adjusted accordingly to maintain a suggested level of 5-15 ng/mL. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
Study: NCT01686165
Drug: belinostat
Normalized name: Belinostat
DrugBank: Belinostat (DB05015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02208037
Drug: Tacrolimus (ARM with MMF and Cyclophosphamide)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day +5. Serum levels of tacrolimus will be measured at Day 7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
Study: NCT00208533
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole 5 mg to 30mg, individually titrated
Study: NCT02494921
Drug: Docetaxel-PNP
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02494921
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given Orally
Study: NCT02494921
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given Orally
Study: NCT02494921
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT02208037
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc will be dosed at 300 mg orally twice a day and will start on Day -3 prior to hematopoietic stem cell infusion, and continue until Day 30 post HSCT. If the patient requires a two-day stem cell infusion, maraviroc treatment will end 30 days after the first infusion day.
Study: NCT00095914
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00095914
Drug: paclitaxel albumin-stabilized nanoparticle formulation
Normalized name: Albumin-stabilized nanoparticle (130 nm)
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02208037
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib will be administered at the dose of 1.3 mg/m2 based upon actual body weight (ABW) as an approximately 3-5 second IV push on Days +1, +4, and +7 after hematopoietic stem cell infusion. There must be at least 72 hours between each dose of bortezomib. Subcutaneous administration of bortezomib is not allowed on this protocol.